<DOC>
	<DOCNO>NCT01324388</DOCNO>
	<brief_summary>The purpose study twofold : 1 . To evaluate effect LY2189265 body absorb blood pressure lower drug ( lisinopril ) participant high blood pressure currently take lisinopril . 2 . To evaluate effect LY2189265 heart rate blood pressure healthy volunteer take Beta-blocker drug ( metoprolol ) . In Part 1 , participant receive four weekly injection LY2189265 continue use normal lisinopril therapy . Part 2 cross-over study design . Participants receive single injection LY2189265 one period , seven daily dos metoprolol single injection LY2189265 another period .</brief_summary>
	<brief_title>A Study Effect LY2189265 Two Blood Pressure Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>Male participant : agree use reliable method birth control study 3 month follow last dose investigational product Female participant : woman childbearing potential due menopause surgical sterilization ( least 6 week post surgical bilateral oophorectomy , hysterectomy tubal ligation ) confirm medical history Have body mass index ( BMI ) 18.5 40.0 kilograms/square meter ( kg/m^2 ) , inclusive time screen Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample per protocol Are reliable willing make available duration study willing follow study restriction Have give write informed consent inform consent form ( ICF ) approve Lilly correspond ethic committee ( EC ) ethical review board ( ERB ) govern site Part 1 : Have control mild moderate hypertension ( supine blood pressure [ BP ] less equal 140/90 millimeter mercury ( mm Hg ) screening , result acceptable deviation judge clinically significant investigator ) . Males females stable medical problem ( include Type 2 Diabetes Mellitus [ T2DM ] ) , investigator 's opinion , significantly alter disposition drug , place participant increase risk participate study , interfere interpretation data may include Have oral antihypertensive medication ( lisinopril daily [ QD ] ) least 3 month prior screen , stable dose least 1 month prior screening , , investigator 's opinion , able safely adhere QD morning dose regimen . Additional medication may permit indicated T2DM Participants ( Part 1 ) : Have T2DM control diet exercise alone stable single oral agent antihyperglycemic medication ( metformin , sulfonylurea , repaglinide , nateglinide , acarbose [ disaccharidase inhibitor ] thiazolidinediones ) least 3 week ( 3 month thiazolidinediones ) prior admission Have hemoglobin A1c ( HbA1c ) value 6.0 % 9.5 % screen within 4 week prior screen Clinical laboratory test result within normal range deem clinically insignificant investigator . Abnormalities serum glucose , serum lipid , urinary glucose , urinary protein consistent T2DM acceptable Part 2 : • Are overtly healthy , determined medical history physical examination Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergy Glucagonlike peptide1 ( GLP1 ) relate compound , include LY2189265 , component formulation Are participant previously complete withdrawn study , take part study investigate LY2189265 GLP1related compound within last 3 month Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have history presence gastrointestinal disorder ( include pancreatitis [ history chronic pancreatitis idiopathic acute pancreatitis ] gall bladder disease ) gastrointestinal disease impact gastric empty ( GE ) ( e.g . gastric bypass surgery , pyloric stenosis ) could aggravate GLP1 analog ( example ; esophageal reflux ) . Participants cholecystectomy ( removal gall bladder ) past sequela , may include study discretion screen physician Have history presence thyroid disease , unless stable dose thyroxine replacement therapy least 1 month Show history evidence significant active neuropsychiatric disease Have personal family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Intend start new concomitant medication study , include overthecounter herbal medication , use drug directly reduce gastrointestinal motility regularly use systemic corticosteroid , potent , inhale , intranasal steroid know high rate systemic absorption Have donate 500 milliliter ( mL ) blood within month prior screen Have nondominant arm circumference great 42 centimeter ( cm ) Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling stop alcohol consumption 48 hour admission discharge unit , limit alcohol intake maximum 2 units/day day screen 48 hour prior followup visit . ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Are participant , opinion investigator , way unsuitable participate study Part 1 : • Have medical condition , medical history take medication contraindicate within lisinopril product information leaflet Part 2 : Intend use overthecounter medication ( exception paracetamol and/or antacid ) within 7 day prior dose prescription medication ( exception vitamin/mineral supplement and/or hormone replacement therapy and/or thyroid replacement therapy ) within 14 day prior dose investigational product Have medical condition , medical history take medication contraindicate within metoprolol product information leaflet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>